Primary sources

These are the main regulatory and clinical records behind the current evidence pages.

• FDA prescribing information: Wegovy (semaglutide), including geriatric use
• Meta-analysis: GLP-1 medicines in adults aged 65 and older with obesity
• Position statement: obesity management in older adults
• American College of Cardiology consensus on high triglycerides
• FDA accelerated approval of Forzinity (elamipretide)
• Randomized human study: elamipretide in adults aged 60–85
• FDA briefing document: MOTS-c-related bulk drug substances
• ClinicalTrials.gov: Phase 2a MOTS-c metabolic study
• Review: BPC-157 and blood-vessel responses
• Cell and rat study: BPC-157, VEGFR2, and blood-flow recovery
• FDA briefing document: BPC-157-related bulk drug substances
• FDA Pharmacy Compounding Advisory Committee meeting and materials, July 23–24, 2026
• FDA briefing document: TB-500-related bulk drug substances
• FDA: certain bulk substances that may present significant safety risks
• ClinicalTrials.gov: BPC-157 hamstring-injury study
• Animal study: BPC-157 after surgical muscle-to-bone detachment in rats
• Randomized human study: topical GHK-Cu after facial laser resurfacing
• ClinicalTrials.gov: topical GHK-Cu for small skin wounds
• WADA 2026 Prohibited List
• WADA committee minutes: decision to name BPC-157 under S0
• FDA prescribing information: PRIALT (ziconotide)
• Randomized trial: intrathecal ziconotide for severe chronic nonmalignant pain
• Randomized trial: slower ziconotide titration for severe chronic pain
• STEP 9 randomized trial: semaglutide in obesity and knee osteoarthritis
• Meta-analysis: collagen supplementation and knee osteoarthritis
• Meta-analysis: analgesic efficacy of collagen peptide in knee osteoarthritis
• Randomized trial: low-molecular-weight collagen peptides in knee osteoarthritis
• FORWARD randomized trial: sprifermin and knee-cartilage thickness
• TPX-100 knee program: blinded MRI bone-shape analysis
• ClinicalTrials.gov: completed TPX-100 paired-knee Phase 2 study
• ClinicalTrials.gov: current 270-person TPX-100 knee study
• ACR abstract: TPX-100 and knee function at 6 and 12 months
• ACR abstract: TPX-100 functional responders and tibiofemoral cartilage
• Early trial: ARA-290 in type 2 diabetes and neuropathic symptoms
• Phase 2b trial: cibinetide in sarcoidosis-associated small-fiber loss
• Cell and mouse study: KPV and intestinal inflammation
• Mouse and cell study: GLP-1-derived peptides and TRPV1 inhibition
• Rodent and cell study: short peptides targeting TRPV4 for mechanical pain
• CDC clinical practice guideline for prescribing opioids for pain
• CDC: Surgical Site Infection Basics

cAmbly research feature — September 10, 2026

The article’s six-source reading list includes the original discovery record, earlier laboratory studies, human biological context, and U.S. pain-survey data. Its review notes identify the source-access limits.

Earlier source list last reviewed August 23, 2026. cAmbly reading list added September 10, 2026.